摘要
目的观察阿托伐他汀对急性冠脉综合征(ACS)患者早期超敏C反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)、血脂及心脑血管事件的干预效果。方法103例ACS患者随机分为阿托伐他汀治疗组(55例)和常规治疗对照组(48例),分析比较组间及阿托伐他汀治疗(10 mg/d)前和治疗后2、4周总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三脂(TG)、hs-CRP和MMP-9水平的变化,同时观察ACS患者半年随访期间主要心脑血管事件发生情况。结果阿托伐他汀(10 mg/d)治疗2周后,仅hs-CRP及MMP-9水平较前明显降低(P<0.05),治疗4周后TC、LDL-C、hs-CRP及MMP-9均显著降低(P<0.05),与常规治疗对照组治疗后相比亦明显下降(P<0.05),阿托伐他汀治疗组半年随访期间复发性心绞痛、心力衰竭、心律失常等均较常规治疗组明显降低(P<0.05)。结论阿托伐他汀早期治疗可以明显降低hs-CRP、MMP-9水平,减轻炎症反应稳定斑块并改善预后。
Objective:To observe the effects of atorvastatin on hight sensitivity C - reactive protein( hs -CRP), matrix metallopreteinase -9 ( MMP- 9), blood lipid and cardiovascular events in patients with acute coronary syndrome (ACS) in early stage. Method: The 103 ACS patients were randomly divided into routine treatment control group ( n =48) and treatment group ( n = 55) with added atorvastatin 10 mg per day with 48 h from onset. The levels ofTC, LDL-C,HDL-C,TG, hs - CRP, and MMP - 9 before and after two and four week treatmet and major cardiovascular events in 6 months were observed. Results : After two weeks treatment with atorvastain 10 mg per day , the levels of hs - CRP and MMP - 9 decreased significantly than per - treatment( P 〈 0.05 ) o After 4weeks treatment, TC, LDL - C, hs - CRP and MMP - 9 were all lowered significantly ( P 〈 0.05 ), Comparing with the general treatment group, they were decreased significantly too ( P 〈 0.05 ). There were relatively lower recurrent angina pectoris, congestive heart failure and arrhypthmia than control group during the 6 months follow up(P 〈 0.05) Conclusion: Comparing with the general treatment group, atorvastain show better effects on decreasing levels of hs - CRP and MMP - 9 in early stage, stable atherosclerotic plaque and improve clinic prognosis.
出处
《泰山医学院学报》
CAS
2006年第7期625-627,共3页
Journal of Taishan Medical College
关键词
阿托伐他汀
急性冠脉综合征
高敏C反应蛋白
基质金属蛋白酶-9
血脂
atorvastatin
acute coronary syndrome
high sensitivity C - reative protein
matrix metaUopreteinase - 9 blood lipid